HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
10 sources retrieved Β· Most recent: April 2026 Β· Index updated 15 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
MORC2
MORC family CW-type zinc finger 2
Chromosome 22 Β· 22q12.2
NCBI Gene: 22880Ensembl: ENSG00000133422.15HGNC: HGNC:23573UniProt: Q9Y6X9
111PubMed Papers
22Diseases
0Drugs
34Pathogenic Variants
FUNCTIONAL ROLE
Highly Constrained
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
magnesium ion bindingchromatin bindingprotein bindingATP bindingCharcot-Marie-Tooth disease axonal type 2Zdevelopmental delay, impaired growth, dysmorphic facies, and axonal neuropathygenetic disorderGrowth delay
✦AI Summary

MORC2 is an ATP-dependent chr22 remodeler that functions as a core component of the HUSH (human silencing hub) complex, essential for epigenetic gene silencing 1. The protein contains an N-terminal GHKL-type ATPase domain and a C-terminal DNA binding region required for gene silencing activity 2. MORC2 specifically silences L1 retrotransposons and germ cell-related genes by promoting H3K9me3 deposition within euchromatic regions, often occurring within introns of active genes and reducing host gene expression 3. The protein's ATPase activity and homodimerization are critical for HUSH-mediated silencing 1. Beyond transcriptional repression, MORC2 participates in DNA damage responses through phosphorylation by PAK1 and dynamic SUMOylation, wherein SUMO modifications regulate transient chr22 relaxation for DNA repair, followed by re-SUMOylation to promote repair completion 4. Post-translational modifications including acetylation at K767 by NAT10 regulate G2 checkpoint control in response to DNA damage 5. Pathogenic variants in MORC2's ATPase module cause developmental disorders characterized by intellectual disability, growth retardation, and neuropathy, with some cases showing Leigh syndrome-like brain lesions 1. MORC2 thus functions as a multi-functional epigenetic regulator integrating chr22 remodeling, transposable element silencing, and DNA damage surveillance mechanisms.

Sources cited
1
MORC2 ATPase activity and homodimerization are critical for HUSH-mediated silencing; variants cause developmental delay, growth retardation, and neuropathy
PMID: 32693025
2
MORC2 and HUSH selectively silence full-length L1s in euchromatin by promoting H3K9me3 deposition, often within introns of active genes, reducing host gene expression
PMID: 29211708
3
MORC2 contains a C-terminal DNA binding region required for gene silencing; DNA binding reduces ATPase activity and MORC2 can topologically entrap multiple DNA substrates
PMID: 38895295
4
Dynamic SUMOylation of MORC2 at K767 orchestrates chromatin remodeling and DNA repair; SUMO depletion induces transient chromatin relaxation enabling DNA repair
PMID: 36793866
5
NAT10-mediated acetylation of MORC2 at K767 regulates DNA damage-induced G2 checkpoint control by repressing CDK1 and Cyclin B1
PMID: 32112098
Disease Associationsβ“˜22
Charcot-Marie-Tooth disease axonal type 2ZOpen Targets
0.83Strong
developmental delay, impaired growth, dysmorphic facies, and axonal neuropathyOpen Targets
0.78Strong
genetic disorderOpen Targets
0.51Moderate
Growth delayOpen Targets
0.48Moderate
microcephalyOpen Targets
0.48Moderate
developmental disabilityOpen Targets
0.48Moderate
Intellectual disabilityOpen Targets
0.48Moderate
Neurodevelopmental disorderOpen Targets
0.43Moderate
neurodegenerative diseaseOpen Targets
0.34Weak
Global developmental delayOpen Targets
0.34Weak
macular degenerationOpen Targets
0.30Weak
Tip-toe gaitOpen Targets
0.30Weak
HypercholesterolemiaOpen Targets
0.24Weak
mathematical abilityOpen Targets
0.21Weak
sensorineural hearing lossOpen Targets
0.18Weak
Charcot-Marie-Tooth diseaseOpen Targets
0.18Weak
Charcot-Marie-Tooth disease type 1Open Targets
0.14Weak
Charcot-Marie-Tooth disease type 4Open Targets
0.11Weak
distal hereditary motor neuropathyOpen Targets
0.11Weak
neuronopathy, distal hereditary motor, autosomal dominantOpen Targets
0.11Weak
Charcot-Marie-Tooth disease, axonal, type 2ZUniProt
Developmental delay, impaired growth, dysmorphic facies, and axonal neuropathyUniProt
Pathogenic Variants34
NM_001303256.3(MORC2):c.754C>T (p.Arg252Trp)Pathogenic
Charcot-Marie-Tooth disease axonal type 2Z|Inborn genetic diseases|Charcot-Marie-Tooth disease|Distal spinal muscular atrophy|not provided|Developmental delay, impaired growth, dysmorphic facies, and axonal neuropathy
β˜…β˜…β˜†β˜†2026β†’ Residue 252
NM_001303256.3(MORC2):c.394C>T (p.Arg132Cys)Pathogenic
not provided|Charcot-Marie-Tooth disease axonal type 2Z|MORC2-related developmental disorder|Developmental delay, impaired growth, dysmorphic facies, and axonal neuropathy|Neurodevelopmental disorder|MORC2-related disorder
β˜…β˜…β˜†β˜†2026β†’ Residue 132
NM_001303256.3(MORC2):c.1270A>G (p.Thr424Ala)Pathogenic
Charcot-Marie-Tooth disease axonal type 2Z|Developmental delay, impaired growth, dysmorphic facies, and axonal neuropathy|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 424
NM_001303256.3(MORC2):c.260C>T (p.Ser87Leu)Pathogenic
Charcot-Marie-Tooth disease axonal type 2Z|not provided|Charcot-Marie-Tooth disease|Global developmental delay|Inborn genetic diseases|Developmental delay, impaired growth, dysmorphic facies, and axonal neuropathy
β˜…β˜…β˜†β˜†2025β†’ Residue 87
NM_001303256.3(MORC2):c.79G>A (p.Glu27Lys)Pathogenic
not provided|Developmental delay, impaired growth, dysmorphic facies, and axonal neuropathy|MORC2-related neurodevelopmental disorders|Charcot-Marie-Tooth disease axonal type 2Z|Neurodevelopmental disorder|Inborn genetic diseases|MORC2-related disorder
β˜…β˜…β˜†β˜†2025β†’ Residue 27
NM_001303256.3(MORC2):c.1181A>G (p.Tyr394Cys)Pathogenic
not provided|Inborn genetic diseases|Charcot-Marie-Tooth disease axonal type 2Z|MORC2-related disorder
β˜…β˜…β˜†β˜†2025β†’ Residue 394
NM_001303256.3(MORC2):c.707A>G (p.Glu236Gly)Pathogenic
Charcot-Marie-Tooth disease axonal type 2Z|Charcot-Marie-Tooth disease
β˜…β˜…β˜†β˜†2025β†’ Residue 236
NM_001303256.3(MORC2):c.71C>T (p.Thr24Ile)Likely pathogenic
not provided|Developmental delay, impaired growth, dysmorphic facies, and axonal neuropathy|Charcot-Marie-Tooth disease axonal type 2Z
β˜…β˜…β˜†β˜†2024β†’ Residue 24
NM_001303256.3(MORC2):c.395G>A (p.Arg132His)Pathogenic
Developmental delay, impaired growth, dysmorphic facies, and axonal neuropathy|not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 132
NM_001303256.3(MORC2):c.798G>C (p.Arg266Ser)Pathogenic
not provided|Charcot-Marie-Tooth disease axonal type 2Z
β˜…β˜…β˜†β˜†2021β†’ Residue 266
NM_001303256.3(MORC2):c.1219T>C (p.Cys407Arg)Likely pathogenic
Charcot-Marie-Tooth disease axonal type 2Z
β˜…β˜†β˜†β˜†2025β†’ Residue 407
NM_001303256.3(MORC2):c.755G>T (p.Arg252Leu)Pathogenic
Charcot-Marie-Tooth disease axonal type 2Z
β˜…β˜†β˜†β˜†2025β†’ Residue 252
NM_001303256.3(MORC2):c.64A>C (p.Asn22His)Likely pathogenic
Developmental delay, impaired growth, dysmorphic facies, and axonal neuropathy
β˜…β˜†β˜†β˜†2024β†’ Residue 22
NM_001303256.3(MORC2):c.810C>G (p.Cys270Trp)Likely pathogenic
Developmental delay, impaired growth, dysmorphic facies, and axonal neuropathy
β˜…β˜†β˜†β˜†2024β†’ Residue 270
NM_001303256.3(MORC2):c.1271C>G (p.Thr424Arg)Pathogenic
Charcot-Marie-Tooth disease axonal type 2Z
β˜…β˜†β˜†β˜†2023β†’ Residue 424
NM_001303256.3(MORC2):c.1217C>T (p.Ala406Val)Likely pathogenic
Charcot-Marie-Tooth disease|not provided|Charcot-Marie-Tooth disease axonal type 2Z
β˜…β˜†β˜†β˜†2023β†’ Residue 406
NM_001303256.3(MORC2):c.259T>C (p.Ser87Pro)Pathogenic
Developmental delay, impaired growth, dysmorphic facies, and axonal neuropathy
β˜…β˜†β˜†β˜†2023β†’ Residue 87
NM_001303256.3(MORC2):c.395G>T (p.Arg132Leu)Pathogenic
Charcot-Marie-Tooth disease axonal type 2Z
β˜…β˜†β˜†β˜†2023β†’ Residue 132
NM_001303256.3(MORC2):c.798G>T (p.Arg266Ser)Likely pathogenic
Charcot-Marie-Tooth disease axonal type 2Z
β˜…β˜†β˜†β˜†2023β†’ Residue 266
NM_001303256.3(MORC2):c.317C>T (p.Ser106Leu)Likely pathogenic
Developmental delay, impaired growth, dysmorphic facies, and axonal neuropathy
β˜…β˜†β˜†β˜†2022β†’ Residue 106
View on ClinVar β†—
Related Genes
MORC1Protein interaction80%MPHOSPH8Protein interaction73%TASORProtein interaction57%CHD1LShared pathway40%CBX3Shared pathway40%PPHLN1Shared pathway33%
Tissue Expression6 tissues
Ovary
100%
Liver
95%
Brain
91%
Heart
88%
Lung
77%
Bone Marrow
54%
Gene Interaction Network
Click a node to explore
MORC2MORC1MPHOSPH8TASORCHD1LCBX3PPHLN1
PROTEIN STRUCTURE
Preparing viewer…
PDB5OF9 Β· 1.81 Γ… Β· X-ray
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
0.30Highly Constrained
pLIβ“˜
1.00Intolerant
Observed/Expected LoF0.22 [0.16–0.30]
RankingsWhere MORC2 stands among ~20K protein-coding genes
  • #4,281of 20,598
    Most Researched111 Β· top quartile
  • #1,700of 5,498
    Most Pathogenic Variants34
  • #1,143of 17,882
    Most Constrained (LOEUF)0.30 Β· top 10%
Genes detectedMORC2
Sources retrieved10 papers
Response timeβ€”
πŸ“„ Sources
10β–Ό
1
Selective silencing of euchromatic L1s revealed by genome-wide screens for L1 regulators.
PMID: 29211708
Nature Β· 2018
1.00
2
A 20-year Clinical and Genetic Neuromuscular Cohort Analysis in Lebanon: An International Effort.
PMID: 34602496
J Neuromuscul Dis Β· 2022
0.90
3
Dynamic SUMOylation of MORC2 orchestrates chromatin remodelling and DNA repair in response to DNA damage and drives chemoresistance in breast cancer.
PMID: 36793866
Theranostics Β· 2023
0.80
4
Biological functions and molecular mechanisms of MORC2 in human diseases.
PMID: 39637946
Mol Cells Β· 2025
0.70
5
De Novo Variants in the ATPase Module of MORC2 Cause a Neurodevelopmental Disorder with Growth Retardation and Variable Craniofacial Dysmorphism.
PMID: 32693025
Am J Hum Genet Β· 2020
0.60